Inger Birgitta Fogelberg
Plus aucun poste en cours
Profil
Inger Birgitta Fogelberg worked as a Director at Visionar Preclinical AB from 2000 to 2011 and as a Principal at Pharmacia AB from 1984 to 1994.
She also held a Principal position at the University of Uppsala.
Anciens postes connus de Inger Birgitta Fogelberg
| Sociétés | Poste | Fin |
|---|---|---|
Visionar Preclinical AB
 Visionar Preclinical AB Miscellaneous Commercial ServicesCommercial Services Visionar Preclinical AB is a CRO specialized on in vivo preclinical contract research and services. The company was founded year 2000 by individuals with extensive experience of preclinical research and development in international pharmaceutical companies. Its customers are small and mid-size companies who work with drugs, biopharmaceuticals, or medical devices. Quality and flexibility are key factors in their work. Its extensive experience makes it possible for them to find unconventional solutions to preclinical matters. It work closely with their Sponsors to develop strategies for cost effective evaluation of drug candidates and to perform necessary regulatory studies for phase I-II clinical trials. | Directeur/Membre du Conseil | 21/11/2011 |
| Pharmacia AB | Corporate Officer/Principal | 01/01/1994 |
| University of Uppsala | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Visionar Preclinical AB
Visionar Preclinical AB Miscellaneous Commercial ServicesCommercial Services Visionar Preclinical AB is a CRO specialized on in vivo preclinical contract research and services. The company was founded year 2000 by individuals with extensive experience of preclinical research and development in international pharmaceutical companies. Its customers are small and mid-size companies who work with drugs, biopharmaceuticals, or medical devices. Quality and flexibility are key factors in their work. Its extensive experience makes it possible for them to find unconventional solutions to preclinical matters. It work closely with their Sponsors to develop strategies for cost effective evaluation of drug candidates and to perform necessary regulatory studies for phase I-II clinical trials. | Commercial Services |
| Pharmacia AB | Health Technology |
